Synonyms: AVL-301 | CO-1686
Compound class:
Synthetic organic
Comment: Rociletinib is an orally bioavailable small molecule, irreversible inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity [2]. This compound was designed to selectively target both the initial activating EGFR mutations and the T790M resistance mutation which confers acquired tumour resistance to first-generation inhibitors such as erlotinib and gefitinib.
Third-generation mutant EGFR inhibitors like rociletinib are being developed to circumvent dose-limiting WT EGFR-driven toxicities such as gastrointestinal toxicity and rash. The progress being made in developing advanced generation EGFR inhibitors is discussed by Yu and Riely (2013) [3] and Ou and Soo (2015) [1]. ![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
The Ki value for activated EGFR carrying the L858R and T790M mutations is 21.5nM, which is >10 times the potency at the wild type receptor [2]. In tumour xenograft and transgenic models rociletinib treatment induces tumour regression in EGFR-mutated NSCLC, with little effect against the wild type receptor expressing cells [2]. |
Selectivity at catalytic receptors | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|